Clinical Trials Logo
  1. Home
  2. Chronic Kidney Disease (CKD)
  3. NCT05755373
  4. Details
NCT05755373 Clinical Trial

A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists

Chronic Kidney Disease (CKD) Clinical Trial

— FLAME-ASCVD  

Official title:
A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT05755373
Other study ID # DAS-7672
Secondary ID U1111-1284-5885
Status Completed
Phase
First received
Last updated
Start date March 24, 2023
Est. completion date May 15, 2023

Study information
Verified date June 2023
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this survey is to collect information for scientific research and to better understand the role of systemic inflammation in identification, treatment and management of patients with ASCVD and CKD. This study is a cross-sectional design conducted among cardiologists in United Kingdom, Italy, Germany, Brazil, Saudi Arabia, Japan, Australia, China, India and France, treating ASCVD and CKD patients. Study participants will be recruited to complete an approximately 20-minute self-administered online survey. Recruitment will be conducted through email and phone. Data is collected though online data collection using a programmed survey.

Recruitment information / eligibility
Status Completed
Enrollment 602
Est. completion date May 15, 2023
Est. primary completion date May 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). 2. Male or female, age above or equal to 18 years at the time of signing informed consent. 3. Is a Cardiologist. 4. Has been in practice greater than or equal to 3 years. 5. Sees at least 15 ASCVD and CKD patients per month. Exclusion Criteria: 1. Previous participation in this study. Participation is defined as having given informed consent in this study 2. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation 3. Does not meet inclusion criteria requirements

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• No treatment given
No treatment given

Locations
Country Name City State
India Novo Nordisk Investigational Site Bangalore

Sponsors (1)
Lead Sponsor Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

India, 

Outcome
Type Measure Description Time frame Safety issue
Primary Cardiologists' perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD. Multi-select from a defined list. Numerical; A 7-point Likert scale for measurement of agreement from 1 "strongly disagree" to 7 "strongly agree". At the time of survey response (Day 1)
See also
  Status Clinical Trial Phase
Completed NCT05422755 - The Clinical Study to Evaluate Immunogenicity of Epodion® in Anemia Associated With CKD Patients
Completed NCT01693029 - Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa Phase 3
Recruiting NCT04064827 - A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD) Phase 3
Completed NCT02218099 - A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease Phase 1/Phase 2
Completed NCT02276742 - Lifestyle Management of CKD in Obese Diabetic Patients N/A
Completed NCT01222234 - Impact of Vitamin D Therapies on Chronic Kidney Disease N/A
Recruiting NCT05106387 - An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive A Kidney Transplant
Completed NCT05373303 - The Clinical Study for Evaluating The Safety And Efficacy Of Epodion® N/A
Completed NCT01247311 - Vitamin D and the Health of Blood Vessels in Kidney Disease N/A
Completed NCT04042350 - Retrospective Analysis Assessing Clinical Risk Factors for Cardiovascular Events and Mortality and Development of a Risk Calculator in Chronic Kidney Disease Stage 5 on Dialysis
Completed NCT02733328 - Assessment of Plasma and NGAL for the Early Prediction of Acute Kidney Injury After Cardiac Surgery in Adults Study
Completed NCT02341664 - Patient and Provider Assessment of Lipid Management Registry
Enrolling by invitation NCT06322641 - A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists
Completed NCT02678000 - Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function Phase 2
Completed NCT02185911 - Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis N/A
Terminated NCT03226899 - A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment Phase 4
Completed NCT02504294 - A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis Phase 3
Active, not recruiting NCT04094831 - Community-based Screening of Chronic Kidney Disease (CKD) and Measure the Impact of Health Education N/A
Completed NCT01810939 - A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) Phase 3
Completed NCT01950819 - Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) Phase 4